Skip to main content

Advertisement

Log in

Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    Article  PubMed  CAS  Google Scholar 

  2. Atkins M, Jones CA, Kirkpatrick P (2006) Sunitinib maleate. Nat Rev 5:279–280

    Article  CAS  Google Scholar 

  3. Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA (2008) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96

    Article  PubMed  Google Scholar 

  4. Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758

    PubMed  CAS  Google Scholar 

  5. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35

    Article  PubMed  CAS  Google Scholar 

  6. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965–972

    Article  PubMed  CAS  Google Scholar 

  7. Steeghs N, Rabelink TJ, Op’t Roodt J, et al (2009) Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol

  8. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860–1869

    Article  PubMed  Google Scholar 

  9. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295–1298

    Article  PubMed  CAS  Google Scholar 

  10. Greenstein AJ, Nguyen SQ, Berlin A et al (2007) Pneumatosis intestinalis in adults: management, surgical indications, and risk factors for mortality. J Gastrointest Surg 11:1268–1274

    Article  PubMed  Google Scholar 

  11. St Peter SD, Abbas MA, Kelly KA (2003) The spectrum of pneumatosis intestinalis. Arch Surg 138:68–75

    Article  PubMed  Google Scholar 

  12. Ho LM, Paulson EK, Thompson WM (2007) Pneumatosis intestinalis in the adult: benign to life-threatening causes. Ajr 188:1604–1613

    Article  PubMed  Google Scholar 

  13. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989

    Article  PubMed  CAS  Google Scholar 

  14. Mir O, Mouthon L, Alexandre J et al (2007) Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99:85–86

    Article  PubMed  Google Scholar 

  15. Loriot Y, Perlemuter G, Malka D et al (2008) Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clinical Practice 5:268–278

    CAS  Google Scholar 

  16. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568

    Article  PubMed  CAS  Google Scholar 

  17. Flaig TW, Kim FJ, La Rosa FG et al (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 27:83–87

    Article  PubMed  Google Scholar 

  18. Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621

    Article  PubMed  CAS  Google Scholar 

  19. Cacheux W, Boisserie T, Staudacher L et al (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19:1659–1661

    Article  PubMed  CAS  Google Scholar 

  20. Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Acknowledgments of research support for the study: none.

Competing interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Romain Coriat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coriat, R., Ropert, S., Mir, O. et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 29, 1090–1093 (2011). https://doi.org/10.1007/s10637-010-9458-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-010-9458-7

Keywords

Navigation